ImmunityBio (IBRX) Total Non-Current Liabilities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Total Non-Current Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 71.18% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 71.18% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 14.96% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $1.5 billion, up from $1.0 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for IBRX reached as high as $1.5 billion in Q1 2026 and fell as low as $726.9 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $955.6 million across 5 years, with a median of $908.6 million in 2023.
• Across the five-year window, Total Non-Current Liabilities jumped 93.69% in 2022 and slipped 20.06% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $790.5 million in 2022, then soared by 37.79% to $1.1 billion in 2023, then declined by 20.06% to $870.7 million in 2024, then rose by 14.96% to $1.0 billion in 2025, then surged by 51.37% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.